An observational study in Hepatocellular Carcinoma, sponsored by Guangxi Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Guangxi Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Carcinoma, Hepatocellular by Guangxi Medical University — 6 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Hepatocellular · Guangxi Medical University.
Among the 34 studies in Carcinoma, Hepatocellular by Guangxi Medical University, this one is one of 8 that started in 2019, is one of 5 observational ones, and was the 26th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →6 of the 34 studies in Carcinoma, Hepatocellular by Guangxi Medical University are open now, in 1 country. Recruiting first, the newest first:
Guangxi Medical University · Sites in China
Ages 18–70
Guangxi Medical University · Sites in China
Ages 18–75 · Healthy volunteers
Guangxi Medical University · Sites in China
Ages 18–75
Guangxi Medical University
Ages 18–75
Guangxi Medical University · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 19
First in 2013; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 100 across the 29 interventional studies, 600 across the 5 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Guangxi Medical University is the lead sponsor of 71 studies on the registry; 14 are open to participants now.
2 of the studies in Carcinoma, Hepatocellular by Guangxi Medical University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05062837Phase 3Guangxi Medical UniversityHepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | 2026-12-30 |
| NCT06405321Guangxi Medical UniversityConversion or Neoadjuvant Therapy in Hepatocellular Carcinoma | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Carcinoma, Hepatocellular by Guangxi Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.
Hepatic resection is one of the curative treatment for patients with early stage hepatocellular carcinoma (HCC) or selected intermediate or advanced disease. However, the postoperative 5-years recurrent rate is up to 70%, for whom recurrence is a major cause of death. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC by official guidelines. At the same time, four randomizead controlled trials about adjuvant immune checkpoint inhibitors for postoperative HCC are ongoing. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for such patients in clinical practice was reported. Therefore, the investigators plan to investigate the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with high-risk factor of HCC recurrence after curative hepatectomy in a prospective cohort study with real word clinical data.
Patients with hepatocellular carcinoma who underwent curative hepatectomy. And then, these patients receive adjuvant immune checkpoint inhibitors therapy or active surveillance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
Drug: Immune Checkpoint Inhibitors Based Adjuvant therapy
Patients in this arm will not receive any adjuvant therapy.
Other: Active surveillance
Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
Patients in this group only receive active surveillance
Recurrence-free survivial
Recurrence-free survival is calculated from the date of liver resection to the date of tumor recurrence or death from any cause, whichever occurred first.
Time frame: 1 year
Overall survival
Overall survival is calculated from the date of liver resection to the date of death from any cause or the date of the last follow-up.
Time frame: 1 year
Recurrence-free survival
Recurrence-free survival is calculated from the date of liver resection to the date of tumor recurrence or death from any cause, whichever occurred first.
Time frame: 3 years
Recurrence-free survival
Recurrence-free survival is calculated from the date of liver resection to the date of tumor recurrence or death from any cause, whichever occurred first.
Time frame: 5 years
Overall survival
Overall survival is calculated from the date of liver resection to the date of death from any cause or the date of the last follow-up.
Time frame: 3 years
Overall survival
Overall survival is calculated from the date of liver resection to the date of death from any cause or the date of the last follow-up.
Time frame: 5 years
Plan to share: Undecided
Started Mar 2019 (actual). Primary completion is estimated for Dec 2030, 141 months after the start.
Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 141 months is above that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangxi Medical University